Key facts
- This page summarizes Erez Aminov's Form 4 filing for MIRA PHARMACEUTICALS, INC. (MIRA).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 01 Apr 2026, 17:00.
Erez Aminov - 30 Mar 2026 Form 4 Insider Report for MIRA PHARMACEUTICALS, INC. (MIRA)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- MIRA
- Reported as of
- 30 Mar 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 01 Apr 2026, 17:00:00 UTC
- Prior SEC filing
- 17 Feb 2026
- Next SEC filing
- 24 Apr 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Erez Aminov
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Erez Aminov filed Form 4 for MIRA PHARMACEUTICALS, INC. (MIRA) on 01 Apr 2026.
Change
- Previous filing in this sequence was filed on 17 Feb 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001986112
Primary reporting owner
Aminov Erez
- Relationship
- Chief Executive Officer, Director
- Address
- C/O MIRA PHARMACEUTICALS, INC., 1200 BRICKELL AVE. SUITE 1950 #1183, MIAMI
- Signature
- /s/ Erez Aminov
- Signature date
- 01 Apr 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MIRA
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- Shares
- +83,500
- Change %
- Price
- $0.000000*
- Shares after
- 83,500
- Date
- 30 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 83,500
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Each restricted stock unit represents a right to receive one share of Issuer's common stock.
Footnote F2
The RSUs were issued to the Reporting Person on the Grant Date, pursuant to the Plan. All of the RSU shall vested on the Grant Date.